Urine comprehensive genomic profiling of urothelial carcinoma patients undergoing intravesical therapy enables detection of actionable DNA mutations associated with drug response and risk stratification
Urine comprehensive genomic profiling of urothelial carcinoma patients undergoing intravesical therapy enables detection of actionable DNA mutations associated with drug response and risk stratification